Barry Raymond Forman

US Patent:

7531578, May 12, 2009

Filed:

Sep 16, 2004

Appl. No.:

10/944577

Inventors:

Barry Forman - Irvine CA, US
Donna Yu - Arcadia CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

A01N 33/02
A01N 43/42

US Classification:

514648, 514324

Abstract:

Disclosed are novel compositions and novel methods for the creation of both the novel compounds and known compounds. Also disclosed are methods for use of the novel compounds for treating a variety of diseases relating to decreasing or preventing activation of estrogen receptors and/or estrogen related receptors.

US Patent:

7544838, Jun 9, 2009

Filed:

Jan 20, 2006

Appl. No.:

11/336515

Inventors:

Barry Forman - Irvine CA, US
Donna Yu - Arcadia CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

C07C 243/18

US Classification:

564148, 564150, 514615

Abstract:

Estrogen-Related Receptor (ERR) modulating compounds and methods for synthesis of said compounds are described.

US Patent:

8119695, Feb 21, 2012

Filed:

Mar 20, 2009

Appl. No.:

12/408557

Inventors:

Barry Forman - Irvine CA, US
Donna Yu - Arcadia CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

A61K 31/35
A61K 31/135

US Classification:

514648, 514451

Abstract:

Disclosed are novel compositions and novel methods for the creation of both the novel compounds and known compounds. Also disclosed are methods for use of the novel compounds for treating a variety of diseases relating to decreasing or preventing activation of estrogen receptors and/or estrogen related receptors.

US Patent:

8338628, Dec 25, 2012

Filed:

May 22, 2008

Appl. No.:

12/125499

Inventors:

Donna D. Yu - Arcadia CA, US
Barry M. Forman - Irvine CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

C07J 17/00
C07J 9/00

US Classification:

552553, 540118

Abstract:

A novel, improved method of synthesizing alkylated bile acid derivatives is provided. Such derivatives include, but are not limited to the active, potent, and selective FXR receptor agonist such as 6-ECDCA and other CA, DCA and CDCA derivatives. The first step of the synthesis selectively oxidates CDCA, CD, or DCA related starting material. An efficient combined deprotonation, trapping, ethylation, deprotection and reduction system is used to produce the desired alkylated bile acid derivatives. This practical synthesis offers a simple and economical pathway suitable for a large-scale manufacturing of alkylated bile acid derivatives including, but not limited to, 6-ECDCA.

US Patent:

8044241, Oct 25, 2011

Filed:

May 29, 2009

Appl. No.:

12/475323

Inventors:

Barry Forman - Irvine CA, US
Donna Yu - Arcadia CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

C07C 243/18

US Classification:

564148, 564147, 564150

Abstract:

Estrogen-Related Receptor (ERR) modulating compounds and methods for synthesis of said compounds are described.

US Patent:

20020022599, Feb 21, 2002

Filed:

Mar 23, 2001

Appl. No.:

09/815300

Inventors:

Timothy Synold - Monrovia CA, US
Isabelle Dussault - Thousand Oaks CA, US
Barry Forman - Newport Beach CA, US

International Classification:

A61K048/00
A61K031/337

US Classification:

514/044000, 514/449000

Abstract:

The present invention relates to new methods of modifying drug clearance and avoiding multi-drug resistance by modifying SXR activity. SXR is a transcriptional activator of MDR1, cytochrome P40-3A4 and cytochrome P40 2C8. SXR activation can significantly increase the metabolic inactivation and efflux of a wide range of chemotherapeutic agents, for example taxanes. Reducing and/or preventing SXR activation therefore diminishes drug resistance and drug clearance and forms the basis of important therapeutic methods which increase the performance of drugs, such as taxanes. Screening and drug identification methods are described which can identify drugs which are not susceptible to SXR related inactivation and increased efflux. In addition, drugs which can reduce these effects for other agents are provided.

US Patent:

20040019027, Jan 29, 2004

Filed:

Apr 11, 2003

Appl. No.:

10/412659

Inventors:

Barry Forman - Irvine CA, US
Isabelle Dussault - Thousand Oaks CA, US

International Classification:

A61K031/573

US Classification:

514/179000

Abstract:

The present invention provides methods for preventing or treating disorders associated with the degradation of cholesterol and bile alcohols through the use of ligands that interact with pregnane X receptors (PXR). In a preferred embodiment, PXR agonists are used to treat disorders associated with sterol 27-hydroxylase (CYP27) deficiency or mutation. The disorders associated with CYP27 deficiency include but not limited to cerebrotendinous xanthomatosis, cataracts, gallstone, tendon xanthomas, atherosclerosis, hepatomegaly, hypertriglyceridemia, and neurological and neuropsychiatric abnormalities such as peripheral neuropathy and dementia. In another preferred embodiment, PXR agonists are used to prevent or treat disorders that can be alleviated by enhancing the degradation of cholesterol or bile alcohols. The disorders that can be alleviated by enhancing the degradation of cholesterol or bile alcohols include, but not limited to, cardiovascular diseases, hypertension, atherosclerosis, dyslipidemia, obesity, hypercholesterolemia, hyperlipidemia, hyperlipoproteinemia, hyperchylomicronemia, hyperbetalipoproteinemia, dysbetalipoproteinemia, hyperprebetalipoproteinemia, mixed hyperlipidemia, cholestasis, cholesterolosis, gallstone, cataracts, and hepatomegaly.

US Patent:

20050009837, Jan 13, 2005

Filed:

May 20, 2004

Appl. No.:

10/849542

Inventors:

Barry Forman - Irvine CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

A61K031/496
A61K031/433
A61K031/427
A61K031/422
A61K031/4245
A61K031/425
A61K031/42
A61K031/4196
A61K031/4178

US Classification:

514254050, 514362000, 514364000, 514365000, 514374000, 514383000, 514397000, 514372000

Abstract:

The present invention relates to methods and compositions for modulating lipogenesis, lipid accumulation and lipid metabolism in a cell. These methods and compositions modulate genes which are controlled by LXRα, including the lipogenic transcription factor SREBP-1c.